MétaCan
Menu
Back to cohort
Record W4416386963 · doi:10.1111/1759-7714.70183

Pathologic Complete Response Predicts Long‐Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo‐Radiotherapy in Stage‐ <scp>III</scp> Non‐Small Cell Lung Cancer

2025· article· en· W4416386963 on OpenAlexaff
Maja Guberina, Martin Metzenmacher, Christoph Pöttgen, Marcel Wiesweg, Nika Guberina, Anja Merkel‐Jens, Diana Lütke‐Brintrup, Servet Bölükbas, Wilfried Eberhardt, Georgios Stamatis, Fabian Doerr, Till Plönes, Christian Pieter Hoffmann, Gregor Zaun, Benedikt Höing, Cornelius Kürten, Emil Mladenov, George Iliakis, David Kersting, Wolfgang P. Fendler, Thomas Gauler, Marcel Opitz, Aleksandar Milošević, Michael Forsting, Felix Nensa, Lale Umutlu, Faustina Funke, Hubertus Hautzel, Ken Herrmann, Christian Taube, Dirk Theegarten, Clemens Aigner, Martin Schüler, Martin Stuschke

Bibliographic record

VenueThoracic Cancer · 2025
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Diagnosis and Treatment
Canadian institutionsArtificial Intelligence in Medicine (Canada)
FundersUniversität Duisburg-Essen
KeywordsInduction chemotherapyComplete responseChemotherapyLung cancerNeoadjuvant therapyStage (stratigraphy)Induction therapyClinical trial

Abstract

fetched live from OpenAlex

ABSTRACT Background To analyze the association of pathologic‐complete‐response (PCR) and survival after neoadjuvant concurrent chemo‐radiotherapy, we evaluated a large cohort of patients with potentially resectable stage IIIA–IIIC non‐small cell lung cancer (NSCLC) treated with a trimodality approach. Methods Consecutive patients underwent neoadjuvant induction chemotherapy, followed by concurrent chemo‐radiotherapy and surgery. Patients received established imaging, and diagnostics. Leave‐one‐out cross‐validation was employed to identify the most effective prognostic classifier. Results Altogether, 403 patients treated between 06/2000 and 01/2020 were included. Median follow‐up was 111 months (IQR: 71–127 months). PCR was achieved in 34% (137 patients) after neoadjuvant therapy and major‐pathologic response without PCR in 30% (MPR &gt; 0%–≤ 10% defined as viable cells in &gt; 0% and ≤ 10% of the sample). PCR was significantly dependent on histology ( p = 0.0005) and radiotherapy fractionation schedule ( p = 0.027). PCR rates were higher for squamous than for non‐squamous carcinoma with 46.2% (95% CI: 37.8%–54.7%) versus 27.3% (95% CI: 22.0%–33.2%). PCR was the most significant prognostic factor for long‐term survival with an associated hazard ratio of 0.272 (0.192–0.386), while MPR was associated with a hazard ratio of 0.671 (0.498–0.905) in comparison to lesser response. Overall survival at 5/10 years with PCR was 72.9% (95% CI: 64.4%–79.6%)/ 62.8% (53.0%–71.1%)/ event‐free survival at 5 years 69.5% (60.9%–76.7%). Identified through cross‐validation, key prognostic features included PCR, MPR, and treatment period following 18 F‐FDG‐PET/CT‐guided staging. Conclusions Induction chemotherapy followed by chemo‐radiotherapy results in high PCR rates. In this investigation, PCR is followed by high event‐free and overall survival rates. These data warrant further investigation of chemo‐radiotherapy as a significant component of neoadjuvant treatment regimens in trials combined with immunotherapy. This strategy may increase the PCR rates, particularly for patients with more advanced, potentially resectable stage III NSCLC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.053
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.344
Teacher spread0.321 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueThoracic CancerSame topicLung Cancer Diagnosis and TreatmentFrench-language works237,207